UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
(State of Incorporation) |
(Commission File Number) |
(IRS employer identification no.) |
(Address of principal executive offices, including zip code)
Registrant’s
telephone number, including area code:
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 7.01 | Regulation FD Disclosure. |
On November 20, 2024, Intelligent Bio Solutions Inc. (the “Company”) released a video explaining the initial results from its Pharmacokinetic (PK) study required for an FDA 510(k) submission.
This video is available for viewing on the Company’s website at www.ibs.inc and going to the news and media section or by using the links below.
https://ibs.inc/2024/11/20/inbs-pk-study-results/
| Item 8.01 | Other Events. |
As a result of the sale of shares of common stock by the Company pursuant to the previously disclosed At The Market Offering Agreement, dated September 18, 2024 (the “ATM Agreement”), between the Company and Ladenburg Thalmann & Co. Inc. (“Ladenburg”), the Company has raised approximately $250,802 (net of commissions of approximately $7,756 paid to Ladenburg) as of November 19, 2024. Of this amount, the Company raised approximately $34,511 (net of commissions of approximately $1,067 paid to Ladenburg) through the sale and issuance of 17,167 shares of common stock between September 18, 2024, through September 30, 2024; and raised approximately $216,291 (net of commissions of approximately $6,689 paid to Ladenburg) through the sale and issuance of 137,115 shares of Company common stock between October 1, 2024, through November 19, 2024.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 20, 2024 | ||
INTELLIGENT BIO SOLUTIONS INC. | ||
| By: | /s/ Spiro Sakiris | |
| Name: | Spiro Sakiris | |
| Title: | Chief Financial Officer | |